• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Exemestane Teva
    / Abic


    Active Ingredient
    Exemestane 25 mg

    Status in Israel
    RX

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Film Coated Tablets

    25 mg X 30

    partial basket chart 46486 5564

    Related information


    Dosage

    The recommended dose is one 25 mg tablet to be taken once daily, preferably after a meal. In patients with early breast cancer, treatment with Exemestane Teva should continue until completion of 5 years of adjuvant endocrine therapy, or until local or distant recurrence or new contralateral breast cancer.In patients with advanced breast cancer, treatment with Exemestane Teva should continue until tumour progression is evident. No dose adjustments are required for patients with hepatic or renal insufficiency
    Children: Not recommended for use in children.


    Indications

    Indicated for the treatment of advanced breast cancer (ABC) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. Exemestane is also indicated for the treatment of postmenopausal women with ABC whose disease has progressed following multiple hormonal therapies.
    Exemestane is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breast cancer following 2-3 years of initial adjuvant tamoxifen therapy.


    Contra-Indications

    Patients with a known hypersensitivity to the active substance or to any of the excipients and in pre-menopausal women and in pregnant or lactating women.


    Special Precautions

    For further information contact the distributor.


    Side Effects

    For further information contact the distributor.

    CLOSE